AJ503 is an oral program of PDE4 inhibitor under candidate selection for the treatment for systemic inflammatory disorders such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, and other inflammatory bowel disease (IBD).
- 60% 60%
- 40% 40%
- 30% 30%
- 15% 15%
- 10% 10%
We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.